Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists

Geron  (Stock symbol: GERN )

149 Commonwealth Drive
Menlo Park, CA 94025
USA
(650)-473-7700
Website Company Summary Management Team
Board

Outside board: (May no longer be on the board) Hoyoung Huh (BiPar Sciences Executive Chairman) Charles J Homcy (Portola Pharmaceuticals President/CEO) Thomas Hofstaetter (VaxInnate President/CEO) Karin Eastham (Burnham Institute for Medical Research COO) Robert Spiegel (Schering-Plough Former Chief Medical Officer) Alex Barkas (Prospect Venture Partners co-Founder) Edwar V Fritzky (Lederle President) Thomas D Kiley (attorney)
Former outside board: Brian Dovey (Domain Associates Partner);  John P Walker (Novacea CEO/Chairman) Charles Hartman (CW Group);  Patrick Latterell (Venrock Associates);  Robert Stein (Ligand Pharma CTO);  Patrick J Zenner (Hoffman-La Roche Former President/CEO)
Company

Business description: Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com. Imetelstat is a novel, first-in-class telomerase inhibitor exclusively owned by Geron and being developed in hematologic myeloid malignancies. Early clinical data suggest imetelstat may have disease-modifying activity through the suppression of malignant progenitor cell clone proliferation, which allows potential recovery of normal hematopoiesis. Ongoing clinical studies of imetelstat consist of IMerge™, a Phase 2/3 clinical trial in lower risk myelodysplastic syndromes (MDS) and IMbark™, a Phase 2 trial in Intermediate-2 to High-risk myelofibrosis. Imetelstat received Fast Track designation from the United States Food and Drug Administration for the treatment of patients with transfusion-dependent anemia due to non-del(5q) lower risk MDS who are refractory or resistant to an erythroid stimulating agent.
Partners include: Castlight HealthCelera GenomicsGE Healthcare MerckSynteni;  ATCC;  Biotechnology Research;  Bohringer;  Cambrex Bio Science Walkersville;  Chiroscience;  Clonetec;  Diannon;  Kyowa Hakko Kogyo;  Pharmacia;  Upjohn
Capital

Recent Fundings: Dec 2012
Capital raised: 53.4M
Ownership: Public  
Stock Symbol: GERN

Last Tweets


 

Last Mentions


Overview
Record updated: Dec 2021
Sector: Biotech
Year Founded: 1990
Headcount: 201-300 as of Dec 2021
Recent Fundings: Dec 2012
Capital Raised: 53.4M
Ownership: Public  
Stock Symbol: GERN